When surveyed, many physicians said the belief that patients had adequate symptom control was why they didn’t add more meds.

More Good News About Oral Contraceptives Dr JoAnn Manson says a recent meta-analysis showing that OCs may have prevented 400,000 cases of endometrial cancer is more evidence that the benefits ...

Pharmacological therapy focused on ARNi, an approved BB for HFrEF ... by 2017 and 2022 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) HF ...

The main goals of the pharmacological treatment of Heart failure with reduced ejection fraction (HFrEF) are the reduction of mortality and the prevention of hospitalizations. However, other outcomes ...

The PARAGON-HF study (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction) investigated the effect of sacubitril-valsartan in heart failure (HF) ...

According to Novartis, Entresto is the first and only angiotensin receptor-neprilysin inhibitor (ARNi) currently FDA-approved for use in the US for the treatment of heart failure and has no ...

J Am Coll Cardiol 2019;73:1264-72. Editorial Comment: Anand IS. What Explains the Benefits of ARNI Therapy in Heart Failure? J Am Coll Cardiol 2019;73:1285-7. Damman K, Gori M, Brian Claggett, et al.

RDN is expected to reduce the onset and progression of cardiovascular diseases including myocardial infarction, heart failure ... cotransporter 2 inhibitors, ARNI: angiotensin receptor-neprilysin ...

Evidence indicates their efficacy in managing heart failure, chronic kidney disease (CKD), and cardiovascular ...

As society ages, the number of patients with heart failure is rapidly increasing. Excessive growth of fibrotic tissue in the ...